2-azaniumyl-5-[2-(1H-imidazol-5-yl)ethylamino]-5-oxopentanoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-azaniumyl-5-[2-(1H-imidazol-5-yl)ethylamino]-5-oxopentanoate
• 化学式: C10H16N4O3
• 分子量: 240.26
• InChiKey: BGNAGOFSEBNIJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.6
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  121
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES
  申请人：OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES"

  公开号：US20170183318A1

  公开（公告）日：2017-06-29

  The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The invention addresses the object of providing a novel agent effective in the treatment of diseases caused by an RNA-containing virus belonging to the Enterovirus, Metapneumovirus, Pneumovirus, Respirovirus, or Alfa-coronavirus genus, and/or by a DNA-containing virus belonging to the Adenoviridae and/or Herpesviridae family, and in the prevention and treatment of asthma exacerbation, chronic obstructive pulmonary disease, mucoviscidosis, conjunctivitis, gastroenteritis, hepatitis, myocarditis; in the prevention and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia, or airway obstructive syndrome.

  本发明涉及医学，包括一种用于预防和治疗由RNA-和DNA-含病毒引起的疾病以及相关疾病的方法，其中该方法包括使用通式I的化合物或其药用可接受盐的有效量。该发明还涉及制备上述化合物的方法，用于预防或治疗由RNA-和DNA-含病毒引起的疾病的药物组合物，该组合物包括通式I的化合物或其药用可接受盐的有效量。该发明解决了提供一种新型药剂的目标，用于治疗属于肠病毒、副呼吸道病毒、呼吸道病毒、呼吸道病毒或阿尔法冠状病毒属的RNA-含病毒引起的疾病，和/或属于腺病毒科和/或疱疹病毒科的DNA-含病毒引起的疾病，并在预防和治疗哮喘急性发作、慢性阻塞性肺疾病、黏液囊病、结膜炎、胃肠炎、肝炎、心肌炎；在预防和治疗流涕、急性和感染性鼻炎、咽炎、鼻咽炎、扁桃体炎、喉炎、喉气管炎、喉气管支气管炎、支气管炎、支气管炎、肺炎或气道梗阻综合征方面具有有效性。
• AMIDE COMPOUNDS AND METHODS FOR THE PRODUCTION AND USE THEREOF
  申请人：Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises"

  公开号：EP3118211A1

  公开（公告）日：2017-01-18

  The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The invention addresses the object of providing a novel agent effective in the treatment of diseases caused by an RNA-containing virus belonging to the Enterovirus, Metapneumovirus, Pneumovirus, Respirovirus, or Alfa-coronavirus genus, and/or by a DNA-containing virus belonging to the Adenoviridae and/or Herpesviridae family, and in the prevention and treatment of asthma exacerbation, chronic obstructive pulmonary disease, mucoviscidosis, conjunctivitis, gastroenteritis, hepatitis, myocarditis; in the prevention and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia, or airway obstructive syndrome.

  本发明涉及医药，包括一种预防和治疗由含RNA和DNA病毒引起的疾病以及伴随疾病的方法，其中该方法包括使用有效量的通式I化合物或其药学上可接受的盐。本发明还涉及制备所述化合物的方法、用于预防或治疗由含 RNA 和 DNA 病毒引起的疾病的药物组合物，所述组合物包含有效量的通式 I 化合物或其药学上可接受的盐。本发明的目的是提供一种新型制剂，有效治疗由肠病毒属、偏肺病毒属、肺炎病毒属、呼吸道病毒属或阿法-冠状病毒属的含 RNA 病毒引起的疾病、和/或属于腺病毒科和/或疱疹病毒科的含 DNA 病毒，以及预防和治疗哮喘加重、慢性阻塞性肺病、粘液粘稠病、结膜炎、肠胃炎、肝炎、心肌炎；预防和治疗鼻炎、急性和感染性鼻炎、咽炎、鼻咽炎、扁桃体炎、喉炎、喉气管炎、喉气管支气管炎、支气管炎、支气管炎、肺炎或气道阻塞综合征。
• NOVEL ZINC COMPLEX, PRODUCTION AND USE OF SAME
  申请人：Obschestvo s Ogranichennoi Otvetstvennostiyu "Z Therapeutics"

  公开号：EP3842445A1

  公开（公告）日：2021-06-30

  The invention relates to a new zinc complex with gamma-L-glutamylhistamine with a metal/ligand ratio of 1/1. In particular, the invention relates to a compound of the formula The complex according to the invention helps to restore the barrier functions of the epithelial tissue and suppresses the aberrant activity of the immune cells. The invention also relates to the method of complex preparation and use of said zinc complex for the treatment of atopic dermatitis and other diseases associated with impaired barrier functions of epithelial tissue and the development of an aberrant inflammatory response. The invention also relates to the use of the prepared complex for inhibiting glutaminyl cyclase. This invention also concerns pharmaceutical compositions comprising a therapeutically effective amount of a compound of the invention.

  本发明涉及一种与γ-L-谷氨酰胺组胺的新锌络合物，其金属/配体比例为 1/1。特别是，本发明涉及一种式如下的化合物 根据本发明的复合物有助于恢复上皮组织的屏障功能，抑制免疫细胞的异常活动。 本发明还涉及复合物的制备方法，以及所述锌复合物用于治疗特应性皮炎和其他与上皮组织屏障功能受损和炎症反应异常发展有关的疾病的用途。 本发明还涉及所制备复合物在抑制谷氨酰胺环化酶方面的用途。 本发明还涉及包含治疗有效量的本发明化合物的药物组合物。
• [EN] NOVEL ZINC COMPLEX, PRODUCTION AND USE OF SAME<br/>[FR] NOUVEAU COMPLEXE DE ZINC, PRODUCTION DE CELUI-CI ET UTILISATION<br/>[RU] НОВЫЙ ЦИНКОВЫЙ КОМПЛЕКС, ЕГО ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ
  申请人：OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU Z THERAPEUTICS

  公开号：WO2020040670A1

  公开（公告）日：2020-02-27

  Изобретение относится к новому цинковому комплексу гамма-L- глутамилгистамина с соотношением металл/лиганд 1/1.. В частности, изобретение относится к соединению формулы (I) Комплекс по изобретению способствует восстановлению барьерных функций эпителиальной ткани и подавляет аберрантную активность клеток иммунной системы. Изобретение также относится к получению комплекса и применению указанного цинкового комплекса для терапии атопического дерматита и других заболеваний, ассоциированных с нарушением барьерных функций эпителиальной ткани и развитием аберрантного воспалительного ответа. Изобретение также относится к применению полученного комплекса для ингибирования глутаминилциклазы. Данное изобретение также относится к фармацевтическим композициям, содержащим терапевтически эффективное количество соединения по изобретению.